Latest filings (excl ownership)
S-1/A
IPO registration (amended)
9 May 24
S-1/A
IPO registration (amended)
8 May 24
8-K
Regulation FD Disclosure
30 Apr 24
S-1/A
IPO registration (amended)
29 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-1/A
IPO registration (amended)
25 Apr 24
S-1
IPO registration
19 Apr 24
8-K
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
18 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
8-K/A
Departure of Directors or Certain Officers
2 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA
7 Feb 24
424B5
Prospectus supplement for primary offering
1 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Feb 24
8-K
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
16 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-K/A
2022 FY
Annual report (amended)
16 Oct 23
8-K
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
20 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Other Events
17 Jul 23
8-K
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
29 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
28 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
DEFA14A
Additional proxy soliciting materials
12 May 23
ARS
2022 FY
Annual report to shareholders
5 May 23
DEF 14A
Definitive proxy
5 May 23
PRE 14A
Preliminary proxy
21 Apr 23
EFFECT
Notice of effectiveness
5 Apr 23
424B3
Prospectus supplement
4 Apr 23
POS AM
Prospectus update (post-effective amendment)
31 Mar 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Regulation FD Disclosure
22 Mar 23
8-K
Other Events
13 Mar 23
8-K
Departure of Directors or Certain Officers
6 Mar 23
424B3
Prospectus supplement
8 Feb 23
EFFECT
Notice of effectiveness
8 Feb 23
D
$4.20 mm in options / securities to be acquired, sold $4.20 mm, 1 investor
7 Feb 23
CORRESP
Correspondence with SEC
3 Feb 23
Latest ownership filings
4
Milton H. Werner
3 Apr 24
4
Garth Lees-Rolfe
2 Apr 24
3
Garth Lees-Rolfe
2 Apr 24
4
DENNIS N BERMAN
5 Jul 23
4
Gisele Dion
5 Jul 23
4
PAUL C GRINT
5 Jul 23
4
Roy Lester Freeman
5 Jul 23
4
Milton H. Werner
3 Mar 23
4
JOSEPH FRATTAROLI
3 Mar 23
SC 13D
FiveT Investment Management Ltd
24 Feb 23
SC 13G/A
Werner Milton H.
16 Feb 23
SC 13D
FiveT Investment Management Ltd
31 Jan 23
4
Gisele Dion
6 Sep 22
3
Gisele Dion
6 Sep 22
4
Milton H. Werner
16 Aug 22
4
Roy Lester Freeman
28 Jun 22
4
PAUL C GRINT
28 Jun 22
4
Elizabeth G. O'Farrell
28 Jun 22
4
DENNIS N BERMAN
28 Jun 22
4
Milton H. Werner
31 May 22
4
Milton H. Werner
23 May 22
4
JOSEPH FRATTAROLI
23 May 22
4
JOSEPH FRATTAROLI
21 Mar 22
4
Milton H. Werner
21 Mar 22
4
JOSEPH FRATTAROLI
9 Mar 22
4
Milton H. Werner
9 Mar 22
SC 13G/A
Werner Milton H.
11 Feb 22
SC 13D
FiveT Investment Management Ltd
11 Jan 22
4
Milton H. Werner
4 Jan 22
SC 13D
FiveT Investment Management Ltd
15 Dec 21
4
Milton H. Werner
19 Nov 21
4
Milton H. Werner
19 Aug 21
4
Elizabeth G. O'Farrell
29 Jun 21
4
PAUL C GRINT
29 Jun 21
4
Roy Lester Freeman
29 Jun 21
4
DENNIS N BERMAN
29 Jun 21
SC 13D
FiveT Investment Management Ltd
21 Jun 21
4
Milton H. Werner
18 May 21
SC 13G
Kalman Daniel
23 Mar 21
SC 13G
Werner Milton H.
11 Feb 21